Leiomyosarcoma – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Leiomyosarcoma – Pipeline Review, H2 2018’, provides an overview of the Leiomyosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma

– The report reviews pipeline therapeutics for Leiomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Leiomyosarcoma therapeutics and enlists all their major and minor projects

– The report assesses Leiomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Leiomyosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories LLC

BeiGene Ltd

Cell Medica Ltd

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Karyopharm Therapeutics Inc

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Nektar Therapeutics

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

PTC Therapeutics Inc

Trillium Therapeutics Inc

Vicore Pharma AB

Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Leiomyosarcoma Overview 5

Leiomyosarcoma Therapeutics Development 6

Leiomyosarcoma Therapeutics Assessment 13

Leiomyosarcoma Companies Involved in Therapeutics Development 25

Leiomyosarcoma Drug Profiles 34

Leiomyosarcoma Dormant Projects 325

Leiomyosarcoma Discontinued Products 326

Appendix 327

List of Tables

List of Tables

Number of Products under Development for Leiomyosarcoma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Leiomyosarcoma Pipeline by Advenchen Laboratories LLC, H2 2018

Leiomyosarcoma Pipeline by BeiGene Ltd, H2 2018

Leiomyosarcoma Pipeline by Cell Medica Ltd, H2 2018

Leiomyosarcoma Pipeline by Eli Lilly and Co, H2 2018

Leiomyosarcoma Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Leiomyosarcoma Pipeline by Karyopharm Therapeutics Inc, H2 2018

Leiomyosarcoma Pipeline by Merck & Co Inc, H2 2018

Leiomyosarcoma Pipeline by Merck KGaA, H2 2018

Leiomyosarcoma Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Leiomyosarcoma Pipeline by Mirati Therapeutics Inc, H2 2018

Leiomyosarcoma Pipeline by Nektar Therapeutics, H2 2018

Leiomyosarcoma Pipeline by Novartis AG, H2 2018

Leiomyosarcoma Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Leiomyosarcoma Pipeline by Pfizer Inc, H2 2018

Leiomyosarcoma Pipeline by PTC Therapeutics Inc, H2 2018

Leiomyosarcoma Pipeline by Trillium Therapeutics Inc, H2 2018

Leiomyosarcoma Pipeline by Vicore Pharma AB, H2 2018

Leiomyosarcoma Pipeline by Yooyoung Pharm Co Ltd, H2 2018

Leiomyosarcoma Dormant Projects, H2 2018

Leiomyosarcoma Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Leiomyosarcoma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports